Skip to main content
OpenTrials
Completed

NCT Number: NCT03172221

Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women

This is a cross-sectional and multicentre clinical trial to study the performance of the Histidine Rich Protein 2 (HRP2) highly sensitive rapid diagnostic test (HS-RDT) for the detection of malaria during pregnancy in low transmission settings from Colombia and Indonesia. The new HS-RDT will be compared with conventional good quality RDTs, microscopy, and NAATs [loop-mediated isothermal amplification (LAMP), nested PCR (nPCR)], in peripheral blood samples with quantitative reverse transcription PCR (qRT-PCR) as reference standard.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Centro de Salud el Reposo, Quibdó, Colombia

Loading trial locations.

About this study

The activities proposed will be performed in the context of health centres receiving pregnant women for antenatal care visit. Finger-prick blood (300 µL) will be collected and used to test for malaria with the HS-RDT, as well as with conventional good quality RDTs, microscopy and local NAATs (LAMP and nPCR). Dried blood spots will also be collected for qRT-PCR testing. Patient information (demographics, obstetric history, malaria prevention measures, etc.) as well as laboratory results will be recorded and entered into a dedicated database.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with confirmed pregnancy and registered to the antenatal care programme in the local health centre
  • Resident for at least 1 year in the study site
  • Age ≥ 15
  • Accepting to participate with willingness to give informed consent (pregnant adolescents younger than 18 y/o (age < 18) will be considered only if they are accompanied by parent or carer if it is requested by local Institutional Review Boards)
  • Willingness to provide finger-prick blood sample at enrolment

Exclusion criteria

  • Past history of malaria and/or antimalarial drugs in the last three months
  • Positive for malaria by microscopy and conventional RDT testing in any previous study screening visit
  • Presence of severe malaria as defined by WHO guidelines at the moment of recruitment
  • Presence of symptoms and signs of other severe disease and central nervous system infections, as defined by WHO guidelines.

Treatment and study plan

HS-RDT

Diagnostic Test

A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.

Other names: ultrasensitive RDT

Primary outcomes

  1. Diagnostic accuracy

    Time frame: 1 year

    Sensitivity, specificity, negative predictive value, positive predictive value, diagnostic odds ratio (DOR) and the area under the receiver operating characteristic curve (AUROC) of HRP2 HS-RDT for the detection of P. falciparum during pregnancy, compared with conventional good quality RDTs, microscopy and NAATs (LAMP, nPCR,), in peripheral blood with qRT-PCR as reference standard.

Sponsors and collaborators

Lead sponsor

Foundation for Innovative New Diagnostics, Switzerland

Other

Collaborators

  • Universidad de Antioquia

Registry information

Official study title

Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women

Acronym: HSRDT MiP

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 1, 2017
Registry last updated
Nov 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.